Heron Therapeutics, Inc. (HRTX)

0.3979 +0.04 (+9.92%) USD  |  NASDAQ  |  Oct 15, 10:53
More

Heron Therapeutics Total Long Term Debt (Quarterly) : 148.15M for June 30, 2026

Total Long Term Debt (Quarterly) Chart

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 148.15M
March 31, 2026 141.63M
December 31, 2025 140.64M
September 30, 2025 139.66M
June 30, 2025 0.00
March 31, 2025 174.97M
December 31, 2024 174.73M
September 30, 2024 175.00M
June 30, 2024 175.52M
March 31, 2024 176.03M
December 31, 2023 176.55M
September 30, 2023 177.00M
June 30, 2023 153.54M
March 31, 2023 154.17M
December 31, 2022 154.78M
September 30, 2022 155.38M
June 30, 2022 155.96M
March 31, 2022 156.52M
December 31, 2021 157.08M
September 30, 2021 161.25M
June 30, 2021 162.00M
March 31, 2021 13.79M
December 31, 2020 14.56M
September 30, 2020 15.30M
June 30, 2020 16.01M
Date Value
March 31, 2020 16.71M
December 31, 2019 12.24M
September 30, 2019 10.78M
June 30, 2019 11.25M
March 31, 2019 11.72M
December 31, 2018 0.00
September 30, 2018 0.00
June 30, 2018 25.00M
March 31, 2018 25.00M
December 31, 2017 25.00M
September 30, 2017 25.00M
June 30, 2017 25.00M
March 31, 2017 53.10M
December 31, 2016 50.00M
September 30, 2016 50.00M
June 30, 2016 0.00
March 31, 2016 0.00
December 31, 2015 0.00
September 30, 2015 0.00
June 30, 2015 0.00
March 31, 2015 0.00
December 31, 2014 0.00
September 30, 2014 0.00
June 30, 2014 0.00
March 31, 2014 0.00

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Tonix Pharmaceuticals Holding Corp. 1.022M
ACADIA Pharmaceuticals, Inc. 59.55M
Alnylam Pharmaceuticals, Inc. 2.942B
Anika Therapeutics, Inc. 23.32M
Savara, Inc. 30.11M